Persistent infections with nonvaccine oncogenic HPV types occur, but probably not often.
In 2008, programs were initiated in the U.K. to immunize adolescent girls against human papillomavirus (HPV) types 16 and 18. However, data on rates of persistent HPV infection in the U.K. are lacking. Investigators analyzed swabs obtained from a pre-2008 study of subclinical pelvic inflammatory disease to determine prevalence, incidence, and persistence of HPV among 2185 sexually active college-aged women. Participants were asked to provide follow-up swabs a median of 16 months after initial assessment.
A total of 2185 women (mean age, 21) participated in the baseline survey. Of these, 18.5% were positive for an oncogenic HPV (5.4% HPV 16 and 2.3% HPV 18). Among 821 women who provided follow-up samples, annual incidence of any oncogenic HPV…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)